PL365163A1 - Aryl fused azapolycyclic compounds - Google Patents

Aryl fused azapolycyclic compounds

Info

Publication number
PL365163A1
PL365163A1 PL01365163A PL36516301A PL365163A1 PL 365163 A1 PL365163 A1 PL 365163A1 PL 01365163 A PL01365163 A PL 01365163A PL 36516301 A PL36516301 A PL 36516301A PL 365163 A1 PL365163 A1 PL 365163A1
Authority
PL
Poland
Prior art keywords
compounds
aryl fused
fused azapolycyclic
azapolycyclic compounds
aryl
Prior art date
Application number
PL01365163A
Other languages
English (en)
Polish (pl)
Inventor
Paige Roanne Palmer Brooks
Jotham Wadsworth Coe
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL365163A1 publication Critical patent/PL365163A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
PL01365163A 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds PL365163A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds
PCT/IB2001/000153 WO2001062736A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
PL365163A1 true PL365163A1 (en) 2004-12-27

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365163A PL365163A1 (en) 2000-02-25 2001-02-08 Aryl fused azapolycyclic compounds

Country Status (40)

Country Link
US (3) US6605610B1 (US07205300-20070417-C00026.png)
EP (2) EP1259489B1 (US07205300-20070417-C00026.png)
JP (1) JP2003524002A (US07205300-20070417-C00026.png)
KR (1) KR100537976B1 (US07205300-20070417-C00026.png)
CN (1) CN1263745C (US07205300-20070417-C00026.png)
AP (1) AP1860A (US07205300-20070417-C00026.png)
AT (2) ATE453643T1 (US07205300-20070417-C00026.png)
AU (2) AU784081B2 (US07205300-20070417-C00026.png)
BG (1) BG65891B1 (US07205300-20070417-C00026.png)
BR (1) BR0108610A (US07205300-20070417-C00026.png)
CA (1) CA2401229C (US07205300-20070417-C00026.png)
CR (1) CR6726A (US07205300-20070417-C00026.png)
CU (1) CU23148A3 (US07205300-20070417-C00026.png)
CY (1) CY1105301T1 (US07205300-20070417-C00026.png)
CZ (1) CZ303203B6 (US07205300-20070417-C00026.png)
DE (2) DE60140965D1 (US07205300-20070417-C00026.png)
DK (2) DK1259489T3 (US07205300-20070417-C00026.png)
DZ (1) DZ3328A1 (US07205300-20070417-C00026.png)
EA (1) EA005316B1 (US07205300-20070417-C00026.png)
EE (1) EE200200475A (US07205300-20070417-C00026.png)
ES (2) ES2263640T3 (US07205300-20070417-C00026.png)
GE (1) GEP20053454B (US07205300-20070417-C00026.png)
HK (1) HK1050894A1 (US07205300-20070417-C00026.png)
HR (1) HRP20020700A2 (US07205300-20070417-C00026.png)
HU (1) HU229482B1 (US07205300-20070417-C00026.png)
IL (2) IL150639A0 (US07205300-20070417-C00026.png)
IS (1) IS2293B (US07205300-20070417-C00026.png)
MA (1) MA26875A1 (US07205300-20070417-C00026.png)
MX (1) MXPA02008311A (US07205300-20070417-C00026.png)
NO (1) NO323608B1 (US07205300-20070417-C00026.png)
NZ (1) NZ519973A (US07205300-20070417-C00026.png)
OA (1) OA12181A (US07205300-20070417-C00026.png)
PL (1) PL365163A1 (US07205300-20070417-C00026.png)
PT (1) PT1259489E (US07205300-20070417-C00026.png)
RS (1) RS51123B (US07205300-20070417-C00026.png)
SI (1) SI1259489T1 (US07205300-20070417-C00026.png)
SK (1) SK12042002A3 (US07205300-20070417-C00026.png)
UA (1) UA74813C2 (US07205300-20070417-C00026.png)
WO (1) WO2001062736A1 (US07205300-20070417-C00026.png)
ZA (1) ZA200206768B (US07205300-20070417-C00026.png)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
KR100551183B1 (ko) * 2001-04-20 2006-02-13 화이자 프로덕츠 인크. 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법
BR0213696A (pt) * 2001-10-31 2004-10-26 Pfizer Prod Inc Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas
RU2004116320A (ru) * 2001-11-30 2005-10-10 Пфайзер Продактс Инк. (Us) Арилконденсированные азаполициклические соединения
ES2282492T3 (es) * 2001-11-30 2007-10-16 Pfizer Products Inc. Composiciones farmaceuticas de liberacion controlada orales de 5,8,14-triazatetraciclo (10.3.1.0(2,11).0(4,9)-hexadeca-2(11)3,5,7,9-pentaeno.
JP5084103B2 (ja) 2002-07-18 2012-11-28 サイトス バイオテクノロジー アーゲー ハプテン担体抱合体およびその用法
EP1554041B1 (en) * 2002-10-22 2012-05-23 EMD Millipore Corporation Multi-sided immersion formation of composite structures and method
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
WO2004063164A1 (en) * 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
WO2004103372A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2004108725A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
EP1648872A2 (en) * 2003-07-21 2006-04-26 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CA2541752C (en) 2003-10-14 2012-01-03 Xenoport, Inc. Crystalline form of gamma-aminobutyric acid analog
JP2007516275A (ja) * 2003-12-23 2007-06-21 ファイザー・プロダクツ・インク 認知増強および精神病性障害のための治療的組合せ
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
KR20070098942A (ko) * 2005-02-24 2007-10-05 화이자 프로덕츠 인코포레이티드 고순도의 치환된 퀴녹살린의 제조 방법
BRPI0710914A2 (pt) * 2006-04-24 2011-09-27 Pfizer Prod Inc forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar
KR20090086071A (ko) * 2006-11-09 2009-08-10 화이자 프로덕츠 인코포레이티드 니코틴 중간체의 다형체
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
NZ586651A (en) * 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
CA2707671C (en) 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
WO2009071687A1 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg Amidomethyl-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US8314235B2 (en) * 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2396327A1 (en) 2009-02-11 2011-12-21 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
EP2438054A1 (en) * 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
KR20180101268A (ko) 2017-03-03 2018-09-12 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
CN114929235A (zh) * 2020-01-03 2022-08-19 布鲁奥科制药有限公司 用于治疗cns病症的化合物和组合物
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
EP0955301A3 (en) 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
PT1076650E (pt) 1998-04-29 2004-05-31 Pfizer Prod Inc Compostos azapoliciclicos fundidos com arilo
JP4676062B2 (ja) * 1999-01-29 2011-04-27 アボット・ラボラトリーズ ニコチン性アセチルコリン受容体リガンドとしてのジアザ２環式誘導体
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
WO2002074050A2 (en) * 2001-03-19 2002-09-26 Sloan Kettering Institute For Cancer Research Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
EP1648872A2 (en) * 2003-07-21 2006-04-26 Pfizer Products Inc. Aryl fused azapolycyclic compounds
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Also Published As

Publication number Publication date
DE60120366T2 (de) 2007-07-05
KR20030005209A (ko) 2003-01-17
MXPA02008311A (es) 2002-12-09
AU2005234671B2 (en) 2008-04-17
HK1050894A1 (en) 2003-07-11
AU2874801A (en) 2001-09-03
MA26875A1 (fr) 2004-12-20
US7144882B2 (en) 2006-12-05
EP1619192B1 (en) 2009-12-30
OA12181A (en) 2006-05-09
US7205300B2 (en) 2007-04-17
NO323608B1 (no) 2007-06-18
JP2003524002A (ja) 2003-08-12
BR0108610A (pt) 2002-11-19
BG65891B1 (bg) 2010-04-30
ATE453643T1 (de) 2010-01-15
ES2336800T3 (es) 2010-04-16
US6605610B1 (en) 2003-08-12
EE200200475A (et) 2003-12-15
YU59602A (sh) 2005-06-10
US20030130261A1 (en) 2003-07-10
DK1619192T3 (da) 2010-03-29
AU784081B2 (en) 2006-02-02
CA2401229A1 (en) 2001-08-30
IS6459A (is) 2002-07-05
CN1263745C (zh) 2006-07-12
HRP20020700A2 (en) 2004-12-31
ATE328872T1 (de) 2006-06-15
DE60120366D1 (de) 2006-07-20
IL150639A (en) 2011-10-31
AP1860A (en) 2008-07-02
CZ303203B6 (cs) 2012-05-23
CY1105301T1 (el) 2010-03-03
KR100537976B1 (ko) 2005-12-21
HUP0204580A2 (hu) 2003-04-28
EA005316B1 (ru) 2004-12-30
ES2263640T3 (es) 2006-12-16
SK12042002A3 (sk) 2004-02-03
SI1259489T1 (sl) 2006-10-31
EP1619192A3 (en) 2006-03-22
EP1259489A1 (en) 2002-11-27
NO20024042D0 (no) 2002-08-23
HU229482B1 (en) 2014-01-28
DK1259489T3 (da) 2006-10-09
CA2401229C (en) 2007-10-02
CU23148A3 (es) 2006-06-29
IS2293B (is) 2007-10-15
CZ20022778A3 (cs) 2003-09-17
CN1406227A (zh) 2003-03-26
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
EA200200716A1 (ru) 2003-02-27
IL150639A0 (en) 2003-02-12
ZA200206768B (en) 2003-09-23
DE60140965D1 (de) 2010-02-11
BG106908A (bg) 2003-04-30
GEP20053454B (en) 2005-02-25
US20030130260A1 (en) 2003-07-10
AU2005234671A1 (en) 2005-12-15
EP1259489B1 (en) 2006-06-07
HUP0204580A3 (en) 2005-04-28
RS51123B (sr) 2010-10-31
AP2002002604A0 (en) 2002-09-30
CR6726A (es) 2003-10-28
EP1619192A2 (en) 2006-01-25
PT1259489E (pt) 2006-08-31
WO2001062736A1 (en) 2001-08-30
DZ3328A1 (US07205300-20070417-C00026.png) 2001-08-30
UA74813C2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
HK1050894A1 (en) Aryl fused azapolycyclic compounds
BG104561A (en) Aryl fused azapolycyclic compounds
PT1029853E (pt) Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
MY140693A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
SE0104332D0 (sv) Therapeutic agents
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
BG104998A (en) Isothiazole derivatives useful as anticancer agents
TW200502221A (en) Novel lactams and uses thereof
BG104983A (en) Aryl fused azapolycyclic compounds
TW200509933A (en) Therapeutic agents
MXPA01007940A (es) Derivados de azabicicloalcano y usos terapeuticos de los mismos.
WO2005007630A3 (en) Aryl fused azapolycyclic compounds
ATE252546T1 (de) 3-(3-hydroxyphenyl)-3-amino-propionamidderivate
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
SI1704154T1 (sl) Novi indeno (2,1a)indeni in izoindol (2,1-a)indoli
MXPA04003688A (es) Compuestos azapoliciclicos condensados con arilo.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)